Target Rating Price Date Firm Type Start $ End $ % Chg. (Past) (Past) Buy 66 10/23/2013 Upgrade 56.73 58.55 3.21% (Hold) -56 Neutral 52 New 5/31/2013 52 58.55 12.60% Coverage (N/A) (N/A) Neutral N/A 5/16/2013 Downgrade 50.01 58.55 17.08% (Outperform) (N/A) Neutral N/A 2/14/2013 Downgrade 46.99 58.55 24.60% (Buy) (N/A) Hold 46 1/25/2013 Downgrade 46.45 58.55 26.05% (Buy) -46 Buy N/A 1/3/2013 Upgrade 41.88 58.55 39.80% (Neutral) (N/A) Hold N/A New 11/20/2012 41.81 58.55 40.04% Coverage (N/A) (N/A) Of the 17 analysits represented in the chart above, the mean conscensus is Medtronic is undervalued and is a prime investment opportunity. Motley Fool analyst , Ted Cooper, calls Medtronic last remaining bargain” and explains sells at a deep discount to its “the “[Medtronic] peers due to a high degree of uncertainty regarding its future cash flows. But a closer look at the company’s diversified product portfolio and future opportunites makes the stock look attractive at current levels53.” The mean analyst target price shows Medtroinc undervalued by $2.62 or 4.5%.
Date Firm Type Rating Target Price Start $ End $ % Chg. (Past) (Past) 10/23/2013 Upgrade Buy 66 56.73 58.55 3.21% (Hold) -56 5/31/2013 New Coverage Neutral 52 52 58.55 12.60% (N/A) (N/A) 5/16/2013 Downgrade Neutral N/A 50.01 58.55 17.08% (Outperform) (N/A) 2/14/2013 Downgrade Neutral N/A 46.99 58.55 24.60% (Buy) (N/A) 1/25/2013 Downgrade Hold 46 46.45 58.55 26.05% (Buy) -46 1/3/2013 Upgrade Buy N/A 41.88 58.55 39.80% (Neutral) (N/A) 11/20/2012 New Coverage Hold N/A 41.81 58.55 40.04% (N/A) (N/A) Of the 17 analysits represented in the chart above, the mean conscensus is Medtronic is undervalued and is a prime investment opportunity. Motley Fool analyst , Ted Cooper, calls Medtronic “the last remaining bargain” and explains “[Medtronic] sells at a deep discount to its peers due to a high degree of uncertainty regarding its future cash flows. But a closer look at the company’s diversified product portfolio and future opportunites makes the stock look attractive at current levels53.” The mean analyst target price shows Medtroinc undervalued by $2.62 or 4.5%.